Gene Therapy for Blindness
Recently a biotech firm in Philadelphia developed the first Food & Drug Administration (FDA) approved gene therapy for blindness. The company, Spark Therapeutics, developed the therapy known as LUXTURNA™, which improves eyesight in persons with confirmed biallelic RPE65 mutation-associated retinal dystrophy, also known as Leber Congenital Amaurosis (LCA). Patients with this genetic mutation have severe […]